Advanced Search

Study Preview



Study Title and Description

Hypoalgesic effect of caffeine in normotensive men and women.



Key Questions Addressed
1 For [population], is caffeine intake above [exposure dose], compared to intakes [exposure dose] or less, associated with adverse effects on cardiovascular outcomes?
  • Comments Comments (
    0
    ) |

Primary Publication Information
  • Comments Comments (
    0
    ) |
TitleData
Title Hypoalgesic effect of caffeine in normotensive men and women.
Author E Keogh,G Witt,
Country
Year 2001
Numbers

Secondary Publication Information
There are currently no secondary publications defined for this study.


Extraction Form: Cardiovascular Design
Design Details
Question... Follow Up Answer Follow-up Answer
What outcome is being evaluated in this paper? Cardiovascular
  • Comments Comments (
    0
    ) |
What is the objective of the study (as reported by the authors)? The current study sought to experimentally raise blood pressure using 250 mg caffeine, and investigate its effects on the cold pressor pain experiences of 25 men and 25 women.
  • Comments Comments (
    0
    ) |
Provide a general description of the methods as reported by the authors. Information should be extracted based on relevance to the SR (i.e., caffeine related methods) Design A placebo-controlled mixed-groups design was employed. The between-groups factor was gender (male vs. female), and the repeated-measure was caffeine condition (caffeine vs. placebo). The dependent variables consisted of various measures of arousal [including blood pressure and heart rate], mood, and pain experience. Participants Fifty students were recruited from Goldsmiths College, University of London. There were 25 women and 25 men between 18 and 49 years of age All participants were run under both the caffeine and placebo conditions. Procedure Participants were initially screened to ensure that they would not respond negatively to both the pain induction task and the ingestion of caffeine. All participants reported that they did not currently suffer from pain, had no history of cardiovascular disease or diabetes, were not currently on any medication (including analgesics), and were regular caffeine consumers. Participants were informed that they would take part in two sessions 1 week apart and at the same time on each day. Participants were asked to observe various restrictions before attending both sessions. At each testing session, participants were required to refrain from consuming alcohol and caffeine-containing products for 12 hr, and food and0or cigarettes for 2 hr. On the day of testing, baseline measures of arousal were taken. Measurements of systolic and diastolic blood pressure and pulse were taken from participants’ dominant arm using an automated sphygmomanometer (Mars oscillometric digital blood pressure monitor, model MS-700). Three readings were taken from the brachial artery on the inner side of the bicep, 2 min apart, at each testing phase and an average calculated. On completion of the baseline measures, participants then drank a cup of decaffeinated coffee. Unknown to participants, on one of the two testing sessions this drink contained 250 mg of caffeine. Although the experimenter was not blind to the allocation of participants to caffeine/placebo condition, great care was taken to ensure the standardization of instructions throughout. The study was fully counterbalanced across groups with respect to order of caffeine administration. After 45 min from caffeine/placebo consumption, arousal measures were taken.
  • Comments Comments (
    0
    ) |
How many outcome-specific endpoints are evaluated? 2
  • Comments Comments (
    0
    ) |
What is the (or one of the) endpoint(s) evaluated? (Each endpoint listed separately) Blood pressure (SBP and DBP)
  • Comments Comments (
    0
    ) |
List additional health endpoints (separately). 2 Heart rate
  • Comments Comments (
    0
    ) |
List additional health endpoints (separately).3
  • Comments Comments (
    0
    ) |
List additional health endpoints (separately).4
  • Comments Comments (
    0
    ) |
List additional health endpoints (separately).5
  • Comments Comments (
    0
    ) |
List additional health endpoints (separately).6
  • Comments Comments (
    0
    ) |
Clinical, physiological, other Physiological
  • Comments Comments (
    0
    ) |
What is the study design? Controlled Trial
  • Comments Comments (
    0
    ) |
Randomized or Non-Randomized? RCT
  • Comments Comments (
    0
    ) |
What were the diagnostics or methods used to measure the outcome? Objective
  • Comments Comments (
    0
    ) |
Optional: Name of Method or short description Measurements of systolic and diastolic blood pressure and pulse were taken from participants’ dominant arm using an automated sphygmomanometer (Mars oscillometric digital blood pressure monitor, model MS-700).
  • Comments Comments (
    0
    ) |
Caffeine (general) Caffeine (general)
  • Comments Comments (
    0
    ) |
Coffee, Chocolate, energy drink, gum, medicine/supplement, soda, tea, other?
  • Comments Comments (
    0
    ) |
Measured or self reported? Measured
  • Comments Comments (
    0
    ) |
Children, adolescents, adults, or pregnant included? Adults
  • Comments Comments (
    0
    ) |
What was the reference, comparison, or control group(s)? (e.g. high vs low consumption, number of cups, etc.) Each subject served as his/her own control (compared pre-drug/post-drug, as well as post-drug vs. post placebo)
  • Comments Comments (
    0
    ) |
What were the listed confounders or modifying factors as stated by the authors? (e.g. multi-variable components of models.  Copy from methods) None
  • Comments Comments (
    0
    ) |
What conflicts of interest were reported? No information provided
  • Comments Comments (
    0
    ) |
Refid 12240665
  • Comments Comments (
    0
    ) |
What were the sources of funding? No information provided
  • Comments Comments (
    0
    ) |




Results & Comparisons

No Results found.